Announced Tue, 1 Sept, 2026 · 15:49 IST
USFDA inspection at Visakhapatnam facility closed with zero observations
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹2884.00
prior close
₹2915.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-2.8-2.0-2.5+0.8+1.9+3.1+2.6+4.7+1.5+0.1+0.6——
Up moveDown movePending
AI summary
USFDA completed a routine GMP inspection at Gland Pharma's VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam between August 24 and September 1, 2026. The inspection was concluded with zero Form 483 observations, meaning no compliance issues were flagged. No financial or operational impact was reported by the company.
Likely market impact
Positive — clean USFDA inspection removes regulatory uncertainty and supports continued US market operations for oncology and API supplies.